Investigational Drug Information for Staurosporine
✉ Email this page to a colleague
What is the development status for investigational drug Staurosporine?
Staurosporine is an investigational drug.
There have been 31 clinical trials for Staurosporine.
The most recent clinical trial was a Phase 2 trial, which was initiated on December 22nd 2017.
The most common disease conditions in clinical trials are Leukemia, Leukemia, Myeloid, Acute, and Leukemia, Myeloid. The leading clinical trial sponsors are National Cancer Institute (NCI), University Health Network, Toronto, and Sidney Kimmel Comprehensive Cancer Center.
There are four hundred and forty-eight US patents protecting this investigational drug and zero international patents.
Summary for Staurosporine
| US Patents | 448 |
| International Patents | 20,548 |
| US Patent Applications | 4,487 |
| WIPO Patent Applications | 2,109 |
| Japanese Patent Applications | 586 |
| Clinical Trial Progress | Phase 2 (2017-12-22) |
| Vendors | 44 |
Recent Clinical Trials for Staurosporine
| Title | Sponsor | Phase |
|---|---|---|
| Testing the Combination of Standard Induction Therapy With Gemtuzumab Ozogamicin and Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia | Fred Hutchinson Cancer Research Center | Phase 1 |
| Testing the Combination of Standard Induction Therapy With Gemtuzumab Ozogamicin and Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia | Oregon Health and Science University | Phase 1 |
| Testing the Combination of Standard Induction Therapy With Gemtuzumab Ozogamicin and Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia | Pfizer | Phase 1 |
Clinical Trial Summary for Staurosporine
Top disease conditions for Staurosporine
Top clinical trial sponsors for Staurosporine
US Patents for Staurosporine
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Staurosporine | ⤷ Sign Up | Heat shock protein 70 (hsp-70) receptor ligands | Duke University (Durham, NC) | ⤷ Sign Up |
| Staurosporine | ⤷ Sign Up | Pyrazol-3-ones that activate pro-apoptotic BAX | Dana-Farber Cancer Institute, Inc. (Boston, MA) | ⤷ Sign Up |
| Staurosporine | ⤷ Sign Up | Substituted indole Mcl-1 inhibitors | Vanderbilt University (Nashville, TN) | ⤷ Sign Up |
| Staurosporine | ⤷ Sign Up | Combined application of isothiocyanate compound and anti-cancer medicine | JC (Wuxi) Company, Inc. (Wuxi, Jiangsu, CN) | ⤷ Sign Up |
| Staurosporine | ⤷ Sign Up | Molecular constructs with targeting and effector moieties | ⤷ Sign Up | |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Staurosporine
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Staurosporine | World Intellectual Property Organization (WIPO) | WO2015148714 | 2034-03-25 | ⤷ Sign Up |
| Staurosporine | Australia | AU2012322660 | 2031-10-11 | ⤷ Sign Up |
| Staurosporine | Australia | AU2017228527 | 2031-10-11 | ⤷ Sign Up |
| Staurosporine | Canada | CA2851788 | 2031-10-11 | ⤷ Sign Up |
| Staurosporine | Canada | CA3173988 | 2031-10-11 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
